Chicago & Koo ... yes, the stage is set for success with Covid. There should be no shortage of effort and funding for Covid trials, given the worldwide gravity and early promise in prevention and recovery. This should be a huge foocal point for getting this drug and company on the map ASAP ... and also help set the stage with BoM2 (although unrelated indications and evaluation studies), further proving the theoretical therapeutic worth of epigenetics MOA's, and specifically ABL. 

Covid is potentially a "golden" key for opening the commercial door, and shortening the valuation wait for BoM2 imho